LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
LENZ Therapeutics (NASDAQ: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, announced its participation in the BofA Securities 2025 Health Care Conference. The company's management will engage in a fireside chat and one-on-one meetings at the conference, scheduled for May 13-15, 2025 in Las Vegas.
The presentation will take place on Tuesday, May 13, 2025, at 9:20am PDT / 12:20pm EDT at the Encore Hotel. A live audio webcast will be available on LENZ's website, with a replay accessible for 12 months following the event.
LENZ Therapeutics (NASDAQ: LENZ), una società biofarmaceutica in fase pre-commerciale che sviluppa colliri a base di aceclidina per la presbiopia, ha annunciato la sua partecipazione alla BofA Securities 2025 Health Care Conference. Il management dell'azienda parteciperà a una discussione informale e a incontri individuali durante la conferenza, prevista dal 13 al 15 maggio 2025 a Las Vegas.
La presentazione si terrà il martedì 13 maggio 2025, alle 9:20 PDT / 12:20 EDT presso l'Hotel Encore. Sarà disponibile una webcast audio in diretta sul sito web di LENZ, con una replica accessibile per 12 mesi dopo l'evento.
LENZ Therapeutics (NASDAQ: LENZ), una compañía biofarmacéutica en etapa precomercial que desarrolla gotas oftálmicas a base de aceclidina para la presbicia, anunció su participación en la BofA Securities 2025 Health Care Conference. La dirección de la empresa participará en una charla informal y reuniones individuales durante la conferencia, programada para el 13 al 15 de mayo de 2025 en Las Vegas.
La presentación tendrá lugar el martes 13 de mayo de 2025, a las 9:20 a.m. PDT / 12:20 p.m. EDT en el Hotel Encore. Habrá una transmisión de audio en vivo disponible en la página web de LENZ, con una repetición accesible durante 12 meses después del evento.
LENZ Therapeutics (NASDAQ: LENZ)는 노안 치료용 아세클리딘 기반 점안액을 개발하는 초기 상업 단계의 바이오제약 회사로, BofA Securities 2025 Health Care Conference에 참여한다고 발표했습니다. 회사 경영진은 2025년 5월 13일부터 15일까지 라스베이거스에서 열리는 이번 컨퍼런스에서 파이어사이드 채팅과 일대일 미팅에 참여할 예정입니다.
발표는 2025년 5월 13일 화요일 오전 9:20 PDT / 12:20 EDT에 앙코르 호텔에서 진행됩니다. LENZ 웹사이트에서 라이브 오디오 웹캐스트가 제공되며, 행사 후 12개월 동안 다시보기 서비스를 이용할 수 있습니다.
LENZ Therapeutics (NASDAQ : LENZ), une société biopharmaceutique en phase pré-commerciale développant des gouttes ophtalmiques à base d’aceclidinium pour la presbytie, a annoncé sa participation à la BofA Securities 2025 Health Care Conference. La direction de l’entreprise participera à une discussion informelle ainsi qu’à des réunions individuelles lors de la conférence, prévue du 13 au 15 mai 2025 à Las Vegas.
La présentation aura lieu le mardi 13 mai 2025 à 9h20 PDT / 12h20 EDT à l’hôtel Encore. Un webcast audio en direct sera disponible sur le site web de LENZ, avec une rediffusion accessible pendant 12 mois après l’événement.
LENZ Therapeutics (NASDAQ: LENZ), ein biopharmazeutisches Unternehmen in der Vorvertriebsphase, das aceclidinbasierte Augentropfen für Presbyopie entwickelt, gab seine Teilnahme an der BofA Securities 2025 Health Care Conference bekannt. Das Management des Unternehmens wird an einem Fireside-Chat sowie an Einzelgesprächen auf der Konferenz teilnehmen, die vom 13. bis 15. Mai 2025 in Las Vegas stattfindet.
Die Präsentation findet am Dienstag, den 13. Mai 2025, um 9:20 Uhr PDT / 12:20 Uhr EDT im Encore Hotel statt. Ein Live-Audio-Webcast wird auf der LENZ-Webseite verfügbar sein, mit einer Wiedergabe, die für 12 Monate nach der Veranstaltung abrufbar ist.
- None.
- None.
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in a fireside chat and one-on-one meetings at the BofA Securities 2025 Health Care Conference taking place May 13- 15, 2025 in Las Vegas, NV.
Details of the event are as follows:
Date: Tuesday, May 13, 2025
Location: Encore Hotel, Las Vegas, Nevada
Time: 9:20am PDT / 12:20pm EDT
A live audio webcast of the BofA Securities 2025 Health Care Conference presentation will be available here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 12 months following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When is LENZ Therapeutics presenting at the BofA Securities 2025 Health Care Conference?
What is LENZ Therapeutics (NASDAQ: LENZ) developing?
Where can I watch LENZ Therapeutics' BofA Securities conference presentation?
What type of company is LENZ Therapeutics (LENZ)?
